데이터셋 상세
미국
Drugs to be Discontinued
Companies are required under Section 506C of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (as amended by the Food and Drug Administration Safety and Innovation Act) to notify FDA of a permanent discontinuance of certain drug products, six months in advance, or if that is not possible, as soon as practicable. These drugs include those that are life-supporting, life-sustaining or for use in the prevention or treatment of a debilitating disease or condition, including any such drug used in emergency medical care or during surgery). The discontinuations provided below reflect information received from manufacturers, and are for informational purposes only.
데이터 정보
연관 데이터
Current and Resolved Drug Shortages and Discontinuations Reported to FDA
공공데이터포털
Information provided to FDA by manufacturers about current drugs in shortage, resolved shortages, and discontinuations of specific drug products.
FDA Notices of Judgment Collection, 1908-1966
공공데이터포털
A digital archive of the published federal notices of judgment (a summary of the final outcome of a court case) for manufacturers and products prosecuted under authority of the 1906 Pure Food and Drug Act (https://fdanj.nlm.nih.gov/)
국민건강보험공단 상병코드 F90과 그 외 F코드의 주 부상병 동시 진료인원
공공데이터포털
1. 진료개시년도: 2019~2022년 - 진료일기준(한의분류 제외, 약국 제외) 2. 건강보험 급여실적(의료급여 제외)이며, 비급여는 제외 - 2023년 6월 지급분까지 반영 3. 질병코드 기준: “주상병 F90 + 부상병 F코드” 또는 “주상병 F코드 + 부상병 F90” - 해당 질병통계 자료는 요양기관에서 환자진료 중 진단명이 확정되지 않은 상태에서의 호소, 증세 등에 따라 일차진단명을 부여하고 청구한 내역을 발췌한 것이므로, 최종 확정된 질병과는 다를 수 있음 ※ 민원인 요청에 따른 제공 건으로 2023-08-10 발췌
Approved Risk Evaluation and Mitigation Strategies
공공데이터포털
The Food and Drug Administration Amendments Act of 2007 gave FDA the authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks.
목록